Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
Noninvasive model minimizes the risk for missing high-risk varices in unresectable HCC
A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.
FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis
Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.
Log in or Sign up for Free to view tailored content for your specialty!
HCV elimination efforts in Georgia lower infections by 61%, may advance reaching 2030 goal
A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.
Q&A: MASH experts emphasize using noninvasive tests to assess response to Rezdiffra
With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.
Nearly 15.6 million Americans using botanical supplements may be at risk for liver injury
Researchers estimated that nearly 15.6 million Americans consumed at least one potentially hepatotoxic botanical product in the past 30 days, similar to usage reports for simvastatin and NSAIDS.
Liver transplant bests chemotherapies for improved survival in colorectal liver metastasis
Patients who underwent liver transplantation vs. alternative therapy for unresectable colorectal liver metastasis had higher progression-free and overall survival, as well as lower rates of recurrence, researchers reported in JAMA Surgery.
Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks
Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.
Model may ‘serve as a starting point’ to identify patients with MASLD at high risk for HCC
A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.
Prevalence of cirrhosis ‘more than double’ in transgender vs. cisgender adults
Transgender adults had “more than double” the prevalence of cirrhosis vs. cisgender adults, as well as higher rates of comorbidities linked to liver disease progression, researchers reported in The American Journal of Gastroenterology.
Up to 13% with dementia may instead have ‘treatable’ HE due to undiagnosed cirrhosis
Up to 13% of patients with dementia have lab values that suggest undiagnosed cirrhosis and possible hepatic encephalopathy, an “easily treatable” cause of cognitive impairment, according to a study in The American Journal of Medicine.
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read